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This review summarixes some of the major advances in the 
investigation of molecular mechanisms underlying both nor- 
mal and abnormal cardiovascular function. Four major areas 
are highlighted including cardiic muscle, the blood vessel, 
atherosclerosis and thrombosiithrombolysis. The remarkable 
strides in understanding multifactorial diseases such as ath- 
erosck?rosis, and the development of innovative new therapies 
such as the use of thrombolytic agents produced by recombi- 
nant deoxyribonucleic acid (DNA) technology, are noted. 
Moreover, it is concluded that the past decade of basic 
research has provided a solid framework for improvements 
in the diagnosis and therapy of other forms of cardiivascular 
disease as well. An evaluation of current trends in basic 
cardiovascular research suggests that diagnostic and thera- 
peutic approaches to disease will increasingly target specific 
molecular processes underlying the pathophysiologic state. 
(J Am Coil Cardiol1989;13:265-82) 
Historical Perspective 
An early appreciation of the importance of molecules to 
overall function of the cardiovascular system may be as- 
cribed to Ringer (l), who in 1882 recognized the key role of 
leaf and phlebotomy for symptoms now understood to be the 
result of heart failure, amyl nitrite and narcotic analgesia for 
angina pectoris and activity restriction for both. The sound- 
ness of the principles underlying these interventions has 
calcium ions in cardiac muscle contraction. Only 
recently, however, has a more comprehensive 
;X :i-“: ??6:: 
understanding of the many molecules that con- ?? 1 + * + * * + g 9 
stitute the cardiovascular system been made 
possible as a result of major advances in several . 
disciplines, most notably, cellular and molecular . 
biology. 
In the beginning years of this century and A N N , v E R s A R y 
even earlier, therapy of cardiovascular diseases _ _ _ _ 
was largely empiric and applied symptomatically ’ y 4 y 
with little ability to target treatments to the underlying 
pathophysiologic process. Such treatments included digitalis 
1 9 8 9 
been borne out and -modern analogs of each 
exist. Nevertheless, a wider range of therapeutic 
approaches has gradually been developed. In the 
last several decades, elucidation of both normal 
and abnormal physiologic mechanisms involving 
the cardiovascular system has made more pre- 
cise and targeted therapeutic interventions pos- 
sible. Pertinent examples include the use of 
diuretic agents for heart failure and bypass graft- 
ing and, more recently, angioplasty to remedy 
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the mechanical obstructions of blood vessels that result in 
angina pectoris and myocardial infarction. Such attention to 
mechanisms has required greater emphasis on quantitative 
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anatomic and physiologic measurements and the use of some 
of the most advanced technology to make these measure- 
ments with increasing precision. This has allowed recogni- 
tion of the relations between asymptomatic abnormalities 
such as hypertension and symptomatic diseases such as 
dilated cardiomyopathy and coronary atherosclerosis and 
has provided the rationale for the development of preventive 
therapy. 
Most recently, investigation of some of the molecular 
processes that underlie mechanical abnormalities has sug- 
gested new approaches to therapeutics that target basic 
mechanisms of disease. Extrapolation of this trend into the 
future promises further evolution of diagnosis and treatment 
to more basic levels and to application progressively earlier 
in time and in the chain of events that lead to disease. 
Understanding the genetic mechanisms that predispose to 
disease and the environmental influences that modify the 
genetic substrate can lead to prevention or cure of many 
cardiovascular diseases. 
A review on the current status of molecular cardiology 
and the areas in which elucidation of basic mechanisms will 
improve future diagnosis and treatment of cardiovascular 
disease can provide only highlights of some of the more 
important developments. Accordingly, we have divided the 
review into four major sections that will cover 1) cardiac 
muscle; 2) the primary components of the blood vessel, 
smooth muscle and endothelium; 3) the multifactorial dis- 
ease, atherosclerosis, which involves interaction between 
several cell types; and 4) thrombosis and thrombolysis. 
Cardiac Muscle 
Mechanisms regulating adrenergic receptor sensitivity or 
density. The cardiac muscle cell possesses an array of 
hormone receptors that are coupled to ionic and metabolic 
pathways that modulate overall contractile and electrophys- 
iologic function of the heart. There has always been partic- 
ular interest in the role of the autonomic nervous system in 
regulation of cardiac function and this interest continues at 
the most basic levels. 
The development of specijc radioligands for measure- 
ment of the number and affinity of alpha- and beta-adrenergic 
receptors and muscarinic cholinergic receptors has provided 
the necessary methodology for assessing changes in receptor 
density associated with pathophysiologic states. Thus, thy- 
roid hormone has been shown to increase cardiac beta- 
receptors (2), whereas heart failure has been associated with 
a decrease in these receptors (3). Moreover, ischemia has 
been linked to an increase in both beta- (4) and alpha- (5) 
adrenergic receptors. 
An important development has been the recognition and 
characterization of changes in adrenergic receptor function 
or density that occur after lengthy exposure of tissues to 
catecholamines. Several mechanisms appear to account for 
adrenergic receptor desensitization. Desensitization not as- 
sociated with a decrease in receptor number is due to 
uncoupling of agonist binding to the receptor from the 
stimulation of adenylate cyclase. The specific blockade in 
this coupling is at the level of G,, the guanine nucleotide- 
binding protein that couples beta-receptor stimulation to 
activation of adenylate cyclase (6). Recent studies (7) have 
shown that a specific protein kinase, beta-adrenergic recep- 
tor kinase or beta-ARK, phosphorylates the beta,-receptor 
initiating the uncoupling process from G,. Beta-ARK can 
only phosphorylate the beta,-adrenergic receptor when cat- 
echolamine is bound (6). Therefore, with sustained receptor 
occupation, a feedback mechanism to attenuate or dampen 
beta-adrenergic stimulation supervenes. In similar fashion, 
the target protein kinase of beta-adrenergic receptor stimu- 
lation, namely, CAMP cyclic adenosine monophosphate- 
dependent protein kinase, can phosphorylate and desensitize 
the alpha,- and beta-adrenergic receptors, and both the 
beta,- and alpha,-adrenergic receptors are substrates for 
protein kinase C (8), which is the target enzyme for dia- 
cylglycerol, a second messenger derived from phosphatidyl- 
inositol metabolism (see later). In all cases examined to date, 
receptor phosphorylation appears to mediate desensitization 
(6). Most recently, a protein phosphatase activity that de- 
phosphorylates the beta,-adrenergic receptor has been iden- 
tified (8a). Therefore, desensitization as a result of phosphor- 
ylation can be reversed. 
Down-regulation of beta-adrenergic receptors requires 
much longer periods of exposure to catecholamines, is 
associated with complete loss of receptors and appears to 
involve an actual decrease in the synthesis of receptor 
protein (9). The recent cloning of complementary deoxyri- 
bonucleic acid (,DNA) for the adrenergic receptors (10,ll) 
and beta-adrenergic receptor genes (12,13) opens new pos- 
sibilities for more sensitive detection of receptor message 
and for determining how receptor expression is regulated at 
the gene level. 
In summary, adrenergic receptors are modulated by a 
variety of molecular processes that serve to dampen effects 
of sustained catecholamine stimulation. There is “cross- 
talk” among receptor populations with, for example, desen- 
sitization of alpha,-receptors by the beta-adrenergic system 
and vice versa. Selective agents for modulation of adrenergic 
receptor function in the future may be targeted at the 
desensitization processes when a more thorough under- 
standing of their contribution to pathophysiology is attained. 
Guanine nucleotide regulatory proteins: coupling receptors 
to effecters. Beyond adrenergic and cholinergic receptors 
are the guanine nucleotide regulatory proteins or G-proteins. 
The G-proteins reside within the sarcolemma and are com- 
posed of three subunits (alpha, beta and gamma). G-proteins 
couple several hormone receptors to ion channels or en- 
zymes (14). The coupling process requires 1) binding of 
the hormone to its receptor, 2) binding of guanosine-5’- 
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Figure 1. Activation of the phospho- 
inositide pathway by hormones. In this 
simplified scheme, a hormone (for 
example, alpha-adrenergic receptor ag- 
onist, M,-muscarinic cholinergic ago- 
nist) activates the enzyme phospholi- 
pase C through guanine nucleotide 
regulatory proteins, or G-proteins. The 
latter consists of three subunits (alpha, 
beta and gamma). The alpha subunit is 
liberated by binding of guanosine-5’-tri- 
phosphate (GTP) and this activated 
form increases the activity of phospho- 
lipase C. Phospholipase C catalyzes 
the formation of inositol-1,4,5-triphos- 
phate (IP,) and diacylglycerol (DG) 
from L-alpha-phosphatidylinositol di- 
phosphate (PIP,). The latter is pro- 
duced by sequential phosphorylation 
of L-alpha-phosphatidylinositol (PI) 
and L-phosphatidylinositol phosphate 
(PIP) by membrane-bound kinases (K, 
and K,). IP, can stimulate release of 
Ca2+ from sarcoplasmic reticulum (SR) 
of smooth muscle and may serve a 
similar function in cardiac muscle. In- 
creases in intracellular Ca2+ activate 
the contractile mechanism. Diacylglyc- 
erol, in concert with Ca2+ and other 
phospholipids, activates protein kinase 
C. A variety of cellular proteins (for 
example, adrenergic receptors, Na’i 
H’ antiporter) can be phosphorylated 
by protein kinase C resulting in modu- 
lation of activity. 
SIGNAL 
PI- PIP- 
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triphosphate (GTP) by the alpha subunit of the G-protein, 3) 
liberation of the alpha subunit from the complex, and 4) 
binding of the alpha subunit to an effector system (for 
beta-adrenergic receptors, this would be adenylate cyclase) 
followed by activation. Activation is terminated by conver- 
sion of GTP to guanosine-5’-diphosphate (GDP) and rebind- 
ing of the alpha subunit to the corresponding complex. 
Modulation of the function of G-proteins occurs at several 
levels. First, there are multiple genes encoding different 
subunit types (15). Second, coupling can be affected by 
nicotinamide-adenine dinucleotide (ADP)-ribosylation cata- 
lyzed by extrinsic agents such as pertussis and cholera 
toxins (14). Finally, G-proteins are substrates for protein 
kinases, most notably protein kinase C (see later) and 
phosphorylation may serve to desensitize the coupling 
mechanism (16). 
In cardiac muscle, stimulatory G-proteins (G,) couple 
beta-adrenergic (both beta, and beta,) receptors to adenyl- 
ate cycluse (17). Muscarinic cholinergic (M,) receptors are 
coupled to atria1 potassium ion channels (18) by different 
G-proteins (GJ, whereas alpha,-adrenergic receptors are 
coupled to phospholipase C (19). When considering patho- 
physiologic modulation (enhancement or dampening) of a 
MUSCLE CELL 
particular receptor-effector pathway, it has, therefore, be- 
come necessary to investigate receptor-G-protein coupling. 
For example, as beta,-adrenergic receptors numerically de- 
cline in the failing human heart (20) beta,-receptors uncou- 
ple from G-protein activation of adenylate cyclase (21). 
Recently, an increase in measurable G-protein has been 
reported (22) in membranes from failing human hearts. 
Moreover, several noncardiac diseases have been shown to 
be associated with alterations in the amount of a particular 
G-protein (23,24). At present, other than the microbial 
toxins, there are no agents that specifically enhance or 
inhibit function of guanine nucleotide regulatory proteins. 
The quest for such agents, as well as continued examination 
of the role of G-proteins in molecular pathophysiology, will 
require considerable emphasis in the future. 
The phosphoinositide pathway: a new second messenger 
system. In the 1960s investigation of the cyclic nucleotides 
adenosine and guanosine monophosphates (CAMP and 
cGMP) as second messengers yielded immense information 
about biochemical regulatory mechanisms in virtually all 
tissues. In a similar fashion, the discovery in the 1970s of 
calmodulin and its role as an intracellular calcium ion (Ca”) 
receptor facilitated the development of new ideas about 
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Figure 2. Biochemical mechanisms modulating intracellular ion 
fluxes and Ca2+ homeostasis in cardiac muscle. The opening of Na+ 
channels by depolarization and subsequent influx of Na+ leads to 
opening of voltage sensitive Ca’+ channels in the sarcolemma. The 
influx of Ca2+ stimulates release of Ca2+ from sarcoplasmic reticu- 
lum through Ca*’ release channels (“ryanodine receptors”). This 
mechanism can be augmented by beta-adrenergic receptor activa- 
tion of cAMP(adenosine monophosphate)-dependent protein kinase 
(PK,), which phosphorylates the sarcolemmal Ca” channel. CAMP 
is inactivated by conversion to 5’-adenosine monophosphate (5’- 
AMP) by action of a phosphodiesterase (PDE). Alpha-adrenergic 
receptor stimulation may increase intracellular Ca*+ through acti- 
vation of phospholipase c(PLC) as described in Figure I. Muscarinic 
cholinergic agonists (M,-CR) diminish intracellular Ca2+ levels by 
antagonizing CAMP-mediated protein phosphorylation and by mem- 
brane hyperpolarization. Ca2+ uptake by a sarcoplasmic reticulum 
(SR) pump is enhanced by phosphorylation of the protein, phospho- 
lamban (PLB). In addition, Ca2+ efflux from cardiac myocytes 
occurs through a sarcolemmal Ca*+ pump. 
intracellular enzyme regulation (25). Although pathways of 
phosphoinositide metabolism have been elucidated over 
several years, only recently has liberation of specific phos- 
phoinositide metabolites been linked to hormone receptor 
systems (26). The phosphoinositide pathway is summarized 
in Figure 1. 
An important site for hormonal regulation of phospho- 
inositide metabolism is the enzyme phospholipase C (PLC), 
which catalyzes the conversion of L-alpha-phosphatidylino- 
sitol diphosphate (PIP,) to inositol-1, 4, Striphosphate (IP,) 
and diacylglycerol(27). Recent studies (19) of several tissues 
have provided evidence for hormonal receptor (for example, 
alpha,-adrenergic, muscarinic-1 and angiotensin) modulation 
of phospholipase C. Moreover, G-proteins appear to couple 
these receptors to phospholipase C activation (19). In car- 
diac muscle, the alpha, receptor is linked to this pathway, 
but the predominant muscarinic cholinergic receptor, which 
is the M, type, is not (28). 
Two products of phosphoinositide metabolism are partic- 
ularly important: diacylglycerol and inositol phosphates. 
Diacylglycerol, in concert with Ca*+ and phosphatidylserine, 
activates protein kinase C (29). As indicated in the discussion 
of adrenergic receptor desensitization, protein kinase C can 
phosphorylate both alpha- and beta-adrenergic receptors, 
uncoupling them from their respective G-proteins. This might 
be an especially important feedback mechanism to attenuate 
the increase in intracellular Ca*+ that occurs in response to 
alpha,-adrenergic receptor stimulation. Protein kinase C also 
phosphorylates cardiac sarcolemmal proteins (30) and acti- 
vates the sodium/hydrogen (Na+/H+) antiporter leading to 
intracellular alkalinization (31). 
Of the several inositol phosphates and cyclic inositol 
phosphate derivatives identijied to date, inositol-1, 4, 5- 
triphosphate (IP,) has engendered the most attention. As 
indicated, it is generated by the action of phospholipase C on 
L-alpha-phosphatidylinositol diphosphate and a major path- 
way for degradation involves conversion of IP, to inositol-1, 
4-diphosphate by the enzyme, S-phosphomonoesterase (27). 
IP, appears to release Ca*+ from sarcoplasmic reticulum of 
smooth muscle (32) and may mediate a similar action in 
cardiac and skeletal muscle (33). 
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Regulation of intracellular ions: pumps, channels and 
antiporters. A variety of processes operate in the cardiac 
myocyte to maintain electrochemical gradients and to regu- 
late the intracellular concentration and movements of Ca’+ 
(Fig. 2). However, elaboration of some of the more impor- 
tant mechanisms regulating levels of intracellular Ca’+ is 
especially relevant to such disease processes as ischemia 
and heart failure. 
The principal entry sites for CN’+ ure the sarcolemmul 
Ca2+ channels that are concentrated in T-tubules and 
opened by membrane depolarization (34). Two sorts of Ca’+ 
channels have been identified, T-type and L-type. The 
L-type Ca 2+ channel that binds dihydropyridines and other 
Ca2+ channel blocking drugs has been isolated and cloned 
from skeletal muscle (35). The prevailing thought is that 
Ca” entry through sarcolemmal Ca’+ channels induces the 
release of much larger amounts of Ca’+ from the sarcoplas- 
mic reticulum (36). A particularly exciting development (37) 
has been the recent identification of a major Ca’+-release 
channel in the sarcoplasmic reticulum. These structures 
appear to open in response to Ca’+ (38) and can be blocked 
by the drug ryanodine (37): hence, the name “ryanodine 
receptors.” Both the L-type Ca2+ channels of the sarco- 
lemma and the Ca’+-release channels of the sarcoplasmic 
reticulum are substrates for protein kinases (39). Moreover, 
the sarcoplasmic reticulum Cal+-release channels are highly 
sensitive to Ca’+-dependent proteolysis (39). The latter 
process may be one of the mechanisms accounting for Cal+ 
overload in myocardial ischemia because proteolysis of the 
channel greatly increases its open time (40). On the other 
hand. phosphorylation of the sarcolemmal L-type Ca” 
channel by CAMP-dependent protein kinase is the mecha- 
nism accounting for the increase in inward Cal+ current 
observed in response to catecholamine stimulation of car- 
diac muscle. The molecular mechanism appears to be an 
increase in the probability of the open state of individual 
channels (41). 
In rrddition to the intrwellular Ca” overload state of 
myocardiul ischemiu (see later). abnormal Ca2+ transients 
and Ca’+ overload have been observed to occur in failing 
human myocardium (42). The latter could be improved by 
administration of ryanodine to isolated muscle strips (42). 
Such experiments suggest that development of pharmaco- 
logic agents directed at the Ca’+ release channel of sarco- 
plasmic reticulum might be useful therapeutically. 
There is (mother puthwry for Ca2+ influx into curdiuc 
myocytes. Sodium ion (Na+) plays a central role in this 
pathway through a Na+/Ca’+ antiporter localized to the 
cardiac sarcolemma (43). Antiporters do not require adeno- 
sine triphosphate (ATP) for translocation of ions. Inhibition 
of the Na+/K+ pump by cardiac glycosides (44) or by 
depletion of ATP in ischemia (45) may lead to increases in 
intracellular Na+ and thereby increase intracellular Ca” 
through Na+!Ca’+ exchange. Moreover, intracellular acido- 
sis (for example, ischemia) or activation of the Na+/H+ 
antiporter by pharmacologic agonists may enhance Ca2+ 
entry through Na+/Ca2+ exchange due to a rise in intracel- 
lular Na’. 
The levels of intracellular Ca2+ in cardiac myocytes are 
reduced during diastole by an ATP-dependent Ca2’ pump 
located in the sarcoplasmic reticulum (46). Inside the sarco- 
plasmic reticulum, Ca2+ may remain in solution or be bound 
to the protein calsequestrin (47). Earlier studies provided 
evidence for beta-adrenergic stimulation of Ca’+ uptake by 
sarcoplasmic reticulum mediated by phosphorylation (that 
is, by CAMP-dependent protein kinase) of the protein phos- 
pholamban (48). The mechanism presumably involves en- 
hanced affinity of the sarcoplasmic reticulum Ca’+ pump for 
Ca’+ and the predominant physiologic consequence is en- 
hanced relaxation rate of the muscle (49). Recent studies (50) 
have shown that phospholamban possesses Ca2+ channel 
activity as well. Therefore, more than one pathway for Ca2+ 
efflux from the sarcoplasmic reticulum may exist. Finally, 
Cal+ may exit the cardiac myocyte through a sarcolemmal 
Ca’+ pump that is stimulated by Ca’+ plus calmodulin and 
by CAMP-mediated phosphorylation (5 I). 
In summary. the elucidation of specific pathways for 
Ca”+ movement in cardiac myocytes and the channels and 
enzyme systems responsible for this movement provides a 
rich framework for developing pharmacologic agents that 
enhance or attenuate levels of intracellular Ca2+. Given the 
important role that Ca2+ serves in both normal and patho- 
physiologic states, such as heart failure and ischemia, the 
development of new kinds of Ca’+ antagonists and agonists 
seems well justified. 
Molecules mediating myocardial injury or repair. The 
recent development of thrombolytic agents and the use of 
balloon angioplasty to alleviate the constricting lesions of 
coronary atherosclerosis in the setting of myocardial infarc- 
tion has created a need for new therapy directed at the 
adverse consequences of reperfusion (52). The phenomenon 
of continued myocardial cell death after reperfusion follow- 
ing a period of ischemia appears to be due to molecular 
alterations brought about by the transient accumulation of 
free radicals both within ischemic myocardium and from 
neutrophils that localize to areas of ischemic myocardium 
after reperfusion. Such “reperfusion injury” does not occur 
to nearly the same extent in the presence of free radical 
scavengers (N-2-mercaptoproprionyl glycine) (53) or en- 
zymes involved in free radical degradation (superoxide dis- 
mutase. catalase) (54). or if the heart is reperfused with 
blood that has been depleted of oxygen or neutrophils 
(55,56). The free radicals originating from the myocardium 
itself arise from the action of xanthine oxidase formed from 
xanthine dehydrogenase in endothelial cells possibly by the 
pH and Ca’+-related activation of a Ca’+-dependent prote- 
ase (57.58). This source of radicals thus could be blocked by 
inhibitors of xanthine oxidase (allopurinol, oxypurinol) or 
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the Ca2+-dependent protease. Treatment with xanthine ox- 
idase inhibitors has been demonstrated to be effective but 
also rather impractical because these must be administered 
for 12 to 18 h before &hernia occurs. 
A more fruitful area of therapeutic research has targeted 
the other source of free radicals, the neutrophil, at the level 
of the cell-cell interactions that enable recognition of and 
localization to areas of recent ischemia. This recognition is 
mediated by the neutrophil membrane antigen complex CD, 
18 (LFA-l/Mac-llpl50, 95), which associates with one or 
more endothelial surface antigens variously called ELAM-1 
(endothelium-leukocyte adhesion molecule-l) (59) and 
ICAM- (intercellular adhesion molecule-l) (60). Expression 
of these endothelial antigens is enhanced in the presence of 
inflammatory cytokines such as tumor necrosis factor (TNF- 
alpha), lymphotoxin (TNF-beta) and interleukin-1 (61,62). 
Neutrophil attachment and subsequent free radical related 
injury may be prevented to a great extent by blocking 
antibodies to either of these surface antigens (63), or theo- 
retically by blocking peptides made to correspond to the 
binding portions of either. 
Expression of the “heat shock” series of proteins can 
occur under a variety of cellular stresses including myocar- 
dial ischemia (64). Although the function and regulation of 
this class of proteins is unknown, it is presumed that they 
play some role in protection or restitution of an injured cell. 
Further information regarding the expression and function of 
these proteins holds promise for understanding the basic 
mechanisms of cellular response to injury. 
Cardiac growth and regulation of gene expression. Under- 
standing the mechanisms that regulate the expression of 
genes that encode the many proteins that constitute cardiac 
muscle is an important objective of molecular cardiology. In 
the adult, cardiac myocytes have reached a state of terminal 
differentiation, such that, despite the presence of nuclei, the 
ability for actual cellular division (and therefore replacement 
of dead tissue) is lost. Although this occurrence suggests the 
appearance of genetic inactivity in the heart, more recent 
studies have shown that a variety of genetic processes are 
involved constantly in regulating adaptation of the heart to 
normal and abnormal physical states. At present, relatively 
little is known about the reasons for the protein phenotypic 
changes that occur during development, under hemody- 
namic stresses such as congestive heart failure or under 
hormonal influences such as that of hyper- or hypothyroid- 
ism. The latter include major shifts in the predominantly 
expressed isoforms of contractile proteins (6.5,66), the Na+/ 
Kf adenosine triphosphatase (ATPase) (67) and in the 
distribution of atria1 natriuretic factor (ANF) (68,69), and 
several other proteins. The relative quantity of classes of 
translated proteins also changes with stress, with the pro- 
portion of myofibrillar elements increasing under pressure 
overload (70) and decreasing with overt congestive heart 
failure (71). At present, it is not known which of these well 
described alterations in protein content constitute physio- 
logic adaptation and which, if any, constitute the basis for 
pathology. Discovery of the proximate stimuli for these 
changes, the controls of the promoter and enhancer DNA 
sequences responsible for regulation of these genes in a 
physiologically coordinated fashion, and the physiologic role 
played by each protein change will be necessary to allow 
identification of appropriate targets for therapeutic interven- 
tion. 
Proto-oncogenes are believed to regulate cell differenti- 
ation, growth and replication (72). It has been found that the 
level of the proto-oncogene c-fos decreases suddenly, and 
afterward the level of c-myc decreases more gradually 
during embryonic development of the rat heart (73). On the 
contrary, pressure overload-induced hypertrophy is associ- 
ated with early expression of c-myc and c-fos as well as heat 
shock protein hsp 70 (73,74); c-myc expression has also been 
noted after stimulation of cardiac myocyte growth by alpha- 
adrenergic agents, phorbol esters and serum (75). Effects of 
various oncogenes on expression of muscle-related genes 
including ion channels as well as contractile elements have 
been studied in noncardiac cells derived from muscle (76), 
but such studies have not yet been fully extended to cardiac 
myocytes. A knowledge of the mechanisms controlling car- 
diac myocyte proliferation and terminal differentiation may 
lead to the development of interventions directed toward 
stimulation of regrowth and regeneration after cell death 
such as that due to myocardial infarction. A transgenic 
mouse that expresses the c-myc oncogene constitutively in 
the heart has been developed (77). Moreover, a transgenic 
mouse transfected with the promotor region of DNA from 
the atria1 natriuretic factor gene ligated to an oncogene, the 
SV40 large T-antigen, has been shown to develop massive 
right atria1 hypertrophy accompanied by supraventricular 
arrhythmias (77a). Such approaches to investigation of the 
mechanisms of action of proto-oncogenes may suggest var- 
ious therapeutic modalities applicable to cardiac hypertro- 
phy or toward regeneration. 
The importance of genetic influences on the myocardium 
is also apparent through the variety of cardiomyopathies 
that have a familial component. Some of these include 
hypertrophic obstructive cardiomyopathy, the dilated car- 
diomyopathy that is X-linked (78), several autosomal domi- 
nant cardiomyopathic kindreds (79,80) and the cardiomy- 
opathies that manifest themselves as the full expression of a 
genetic defect involving both skeletal and cardiac muscle, 
such as Duchenne and Becker muscular dystrophy and 
myotonic dystrophy. The long QT syndromes variously 
referred to as Lange-Nielsen, Jervell and Romano-Ward 
may involve inherited abnormalities most prominently af- 
fecting cardiac conduction tissue. The underlying genetic 
abnormality has not been described for any of these human 
diseases with the exception of the recent discovery (81) of 
dystrophin as the protein that is greatly reduced in Duchenne 
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and Becker muscular dystrophies. This protein was found 
with use of the techniques of “reverse genetics,” which 
could isolate the unique genetic abnormality repeatedly 
associated with the disease before any knowledge of the 
associated protein. Current evidence suggests that dystro- 
phin is a component of the transverse tubular membranes 
(82). The T-tubules are involved in excitation-contraction 
coupling, and dystrophin appears to anchor these structures 
to cytoplasmic elements (83). This anchoring may be impor- 
tant for proper alignment of the major membrane compo- 
nents mediating excitation-contraction coupling. 
Similar techniques are being applied to some of the other 
diseases mentioned and should lead to understanding of their 
molecular bases as well. Familial hypertrophic obstructive 
cardiomyopathy is a particularly important disease for inves- 
tigation, as it is a major cause of sudden death in young 
adults (84,85). Given that its major histologic abnormality is 
myocardial disorganization at each of the levels of fiber 
bundles, fibers and myofibrils (86), it has been postulated 
that its molecular defect relates to one of the intermediate 
filament proteins that seem important in myofibrillar struc- 
ture (87). 
Endocrine functions of the heart. Recently the capacity of 
the heart to function as a volume monitor and endocrine 
organ that secretes atria1 natriuretic factor in response to 
increased intravascular volume has been appreciated (88). 
Although the majority of secretory activity typically takes 
place in the atria, it has been noted more recently that a 
remarkably high degree of induction of atria1 natriuretic 
Figure 3. Major pathways influencing contractility of smooth muscle 
ofthe blood vessel wall. Ca2+ can enter smooth muscle cells through 
voltage-sensitive sarcolemmal Cal+ channels. Moreover, a variety 
of hormones or pharmacologic agents can activate the phosphoino- 
sitide pathway as described in Figure 1 leading to release of Ca*+ 
from sarcoplasmic reticulum. Ca *+ bound to calmodulin initiates 
contraction by activating myosin light chain kinase (MLCK). Acti- 
vation of CAMP-dependent protein kinase (PK,) or cyclic guanosine 
monophosphate (cGMP) dependent protein kinase (PK,) through 
their respective pathways leads to smooth muscle relaxation. Atrial 
natriuretic factor (ANF) and endothelium-derived relaxation factor 
(EDRF) activate the cGMP pathway. The divergent effects of 
certain agents (serotonin, acetylcholine) that can stimulate either 
contraction or relaxation of smooth muscle depends on whether a 
normal endothelium is present or not. Normally, these agonists 
stimulate release of EDRF from endothelium inducing relaxation 
Endothelin is a vasoconstrictor released from endothelium. The 
pharmacology of this peptide and its mechanism of action are 
unknown. 
factor expression occurs in the ventricles in the setting of 
significant hemodynamic stress (89). The function of this 
latter expression is unknown at present. The classic endo- 
crine function of atria1 natriuretic factor, to enhance natri- 
uresis while reducing blood pressure, is mediated by a 
receptor that activates guanylate cyclase (90). Moreover, a 
receptor has been cloned that may represent a distinct 
subtype (91) among the three receptors for which evidence 
currently exists (91a). Formation of cGMP and subsequent 
activation of cGMP-dependent protein kinase (Fig. 3) results 
in smooth muscle relaxation (92). Efforts to discover agents 
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that function to elevate cGMP in a similar way either through 
the atria1 natriuretic factor receptor or independently of it 
are underway and should lead to useful agents for reducing 
systemic resistance without increasing sodium retention. A 
peptide analog of atria1 natriuretic factor, anaritide, has been 
developed for this purpose and is currently undergoing 
clinical trials (93). The mode of regulation of atria1 natriuretic 
factor synthesis and release is not well understood but would 
presumably involve a pressure- or stretch-sensitive receptor 
in myocardium. The identity of these receptors has yet to be 
established. 
The Blood Vessel: Smooth Muscle 
and Endothelium 
Regulation of blood vessel tone. The source of muscular 
force in vasculature is smooth muscle that constitutes the 
medial layer of the vessel. The molecular mechanisms that 
account for the generation and maintenance of tone by 
smooth muscle are different from those in cardiac muscle. 
Teleologically, the task of the blood vessel is to maintain 
tone for protracted periods of time. It is not surprising, then, 
that the contractile mechanism in vascular muscle is energy 
efficient (94). The molecular nature of this mechanism is only 
partially characterized but appears to involve attached cross 
bridges that cycle very slowly (95). To some extent sustained 
tension in vascular muscle resembles the rigor state in 
cardiac or skeletal muscle and is also analogous to at least 
one analogy in nature, the “catch state” of the mollusk (96). 
The energy efficiency of the mechanism is the direct result of 
slow cross-bridge cycling. Cross-bridge cycling consumes 
ATP and the slower the cycling, the less ATP that is needed 
to maintain tone. 
The generation and maintenance of tone by vascular 
muscle requires CL?’ (97). Some of the molecular pathways 
involved in regulating intracellular Ca2’ as well as mediators 
of contraction and relaxation are summarized in Figure 3. 
The initial molecular events involved in force generation 
have been extensively described and involve activation of an 
enzyme, myosin light chain kinase, by Ca2+ an the Ca2+- 
binding protein, calmodulin (98). The latter binds certain 
classes of drugs such as phenothiazines and the CaZf chan- 
nel blocker verapamil(99). This interaction may account, in 
part, for the vasodilating effects of these agents. Myosin light 
chain kinase activates cross bridge cycling in smooth muscle 
by phosphorylating the regulatory light chain subunits of 
myosin and the cycling of cross bridges is the mechanism for 
development of tone (100). With prolonged contraction, a 
second mechanism is activated that appears to capture cross 
bridges in a “latch state.” This mechanism requires only 
very low levels of Ca2+ and most likely operates by inhibit- 
ing the detachment of cross bridges (101). Recently, an 
actin-binding protein, caldesmon, has been implicated in the 
formation of the “latch state” in vascular muscle and 
phosphorylation of this protein in response to selective 
agonists may account for latching (102,103). Elucidation of 
the molecular mechanism(s) accounting for the “latch state” 
in vascular muscle may lead to the development of newer 
agents for controlling blood vessel tone or preventing vaso- 
spasm. 
Interactions between blood vessels and endothelium. 
Blood vessel tone results from the interaction of autonomic, 
endothelial, autacoid and hormonal influences. Prosta- 
glandins (104) leukotrienes (105), peptide hormones (106) 
platelet factors (107) catecholamines and various neuro- 
transmitters (108) are the specific substances that mediate 
vasomotion. Segmental vasospasm is an important patho- 
logic concomitant of atherosclerosis. Under these circum- 
stances, abnormal endothelium, activated platelets (109) and 
accumulations of certain neurotransmitter substances (that 
is, serotonin, histamines) in adventitial mast cells or nerve 
endings (110) are especially important cofactors in the patho- 
genesis of vasospasm. 
The role of the endothelium in modulation of blood vessel 
tone has achieved considerable prominence. An important 
discovery was the finding that endothelium releases endo- 
thelium-derived relaxation factor (EDRF) (11 l), most likely 
nitric oxide (NO) (112), in response to several pharmacologic 
agents including bradykinin (113) and acetylcholine. EDRF 
is a potent vasodilator that activates the enzyme guanylate 
cyclase in vascular muscle, increasing the levels of cGMP 
(114). Although the intracellular site or sites of action of 
cGMP-dependent protein kinase, the target enzyme for 
cGMP, is unknown, increases in cGMP are associated with 
a decrease in intracellular Ca” (115), which in turn results in 
relaxation of the muscle. 
Injury, hyperlipidemia (116) and atherosclerosis (117) 
impair EDRF release by many agents. Therefore the release 
of serotonin by activated platelets, which normally results in 
vasodilation through EDRF, causes vasoconstriction (109). 
Moreover, the effect of platelet factor 4, an EDRF-depen- 
dent vasodilator, is blunted (107). 
Investigation of the nature and mechanism of action of 
EDRF has additionally stimulated new efforts to understand 
the molecular pharmacology of nitrate tolerance (118). 
Nitrates activate smooth muscle guanylate cyclase directly. 
However, the active form of the nitrate is a nitrosothiol 
(119). Tolerance may be associated with depletion of sulthy- 
dry1 compounds by excess nitrates. Clinical studies have 
shown that intravascular administration of N-acetylcysteine 
inhibits the development of tolerance (120). 
Quite recently endothelium has been shown to be the 
source of another vasoactive substance, endothelin (121). 
Endothelin is a 21 amino acid peptide that is synthesized as 
preproendothelin (122). The active peptide is released by 
proteolytic processing of the precursor form. Although the 
physiologic and pharmacologic agents that can release en- 
dothelin are not yet known, the peptide is a potent vasocon- 
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strictor (123). Moreover, the potential role of endothelin in 
such disorders as vasospasm and hypertension remains to be 
explored. Nevertheless, the recent discovery of this natu- 
rally occurring vasoconstrictor serves to emphasize the 
considerable work required to understand the many factors 
that are involved in regulating blood vessel tone. 
Atherosclerosis 
Atherosclerosis is a disease that involves complex inter- 
play of all the components of the blood vessel wall with each 
other as well as with both soluble and formed blood ele- 
ments. In recent years, much has been learned about the 
specific secreted and membrane-bound molecules involved 
in normal cell-cell communications and the perturbations in 
these that underlie atherosclerosis. The variety of these 
agents, ranging from small molecules derived from amino 
acids, nucleotides or lipids (for example, serotonin, adeno- 
sine diphosphate (ADP), thromboxane AZ, prostacyclin) to 
peptides and large protein complexes (for example, platelet- 
derived growth factor, transforming growth factor-beta, von 
Willebrand factor, low density lipoprotein), provides for 
many possible negative and positive feedback loops among 
the elements of the blood vessel wall (Fig. 4). Several 
reviews have outlined various perspectives on atherosclero- 
Figure 4. Paracrine and autocrine interactions in atherosclerosis. 
This figure illustrates some of the complex paracrine and autocrine 
interactions that occur between and among the cells playing major 
roles in atheroma formation. It has been simplified by eliminating 
coagulation factors and arachidonic acid derivatives. Molecules 
with predominantly stimulatory function, which here may refer 
either to growth, contraction, adhesion, secretion or gene expres- 
sion, are depicted with solid lines. Molecules with inhibitory func- 
tion with regard to any of the above are depicted with broken lines 
among the endothelium, smooth muscle, macrophages and platelets. 
Interactions with other cells and autocrine interactions are all shown 
with solid lines for simplicity. 
The figure suggests the many possibilities for counterproductive 
positive feedback loops when the balances of stimulation and inhibi- 
tion are disturbed. Moreover, it highlights the centrality of the 
bidirectional interactions between the smooth muscle cell and the 
endothelial cell, and suggests the wide importance of the growth 
factors platelet-derived growth factor (PDGF) and the ECGNFGF 
(endothelial cell growth factor) group, the interleukin (IL-l) that 
functions particularly as a switch to turn on (or ofI) other genes and 
the growth inhibitor TGF-beta. The small vasoactive molecules 
serotonin (5-HT) and endothelial-derived relaxation factor (EDRF) 
(nitric oxide, NO). which are stimulatory and inhibitory, respectively, 
to smooth muscle growth are depicted. Endothelin, a powerful 
vasoconstrictor, also possesses mitogenicity (127a). Adenosine-5 
diphosphate (ADP) is shown parenthetically as a molecule important 
in causing EDRF release from endothelial cells. The role in cell injury 
of low density lipoproteins (LDL) Lp(a), oxygen radicals, and M- 
LDL, the oxidatively modified LDL, are represented. Finally are 
shown the surface molecules of endothelial cells that mediate macro- 
phage/monocyte attachment (the intercellular adhesion molecules 
[ICAM]) and those that suppress smooth muscle growth (the heparin- 
like molecules). 
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sis with particular focus on various of these communication 
pathways (124-127). 
Initiation and progression of atherosclerosis. The typical 
initiation and progression of atherosclerosis have been ob- 
served to have certain characteristic features occurring in 
sequence: 1) the attraction of circulating monocytes to an 
area of endothelium followed by passage between cells to 
form a subendothelial layer of activated macrophages; 2) the 
gradual uptake of lipid by these macrophages to form foam 
cells; 3) the migration from the media and progressive 
replication of smooth muscle cells in the intima to form 
crescentic masses; 4) the conversion of some of these 
myocytes to form foam cells; 5) the secretion of extracellular 
matrix in and around the lesion; and 6) necrosis and calcifi- 
cation of cells and matrix within the lesion. At some point 
concomitant with these events, gaps in the endothelial layer 
are observed and localization of degranulating platelets is 
noted adherent to such areas. These structural changes set 
the stage for the functional changes recognized as contrib- 
uting to a majority of sudden cardiac events (128-13 1): loss 
of the nonthrombogenic property of the normal intact endo- 
thelial lining, leading to thrombosis, and the exaggerated 
tendency to vasospasm that has been shown in atheroscle- 
rotic arteries (110,116,117,132). 
Endothelial cell injury. The theory of Ross and Glomset 
(127,133,134) focuses on endothelial cell injury as the cause 
for monocyte adhesion and the progression described. These 
changes may occur in the absence or the presence of 
endothelial separation or regional “denudation.” Many in- 
vestigators (135-137) have focused on the role of elevated 
circulating lipids as one of the known primary risk factors 
that operate in the absence of endothelial denudation. The 
mechanism by which hyperlipidemias cause the initial endo- 
thelial injury is not clear but may involve either uptake of 
oxidized LDL (low density lipoprotein), discussed later 
(138), or changes in physicochemical membrane properties 
(135,136). The mechanical stimuli of both hypertension 
and turbulent flow are sensed by endothelium and alter 
endothelial metabolism and ion fluxes. Turbulence induces 
a mitogenic response that could explain its atherogenicity 
(139,140). Later in the disease, the separation or loss of 
endothelium causes exposure of the thrombogenic subendo- 
thelium and resultant platelet attraction and aggregation. 
Injury to endothelium by any of these means causes 
binding of blood monocytes, possibly by enhanced expres- 
sion on the endothelial surface of association molecules 
similar to the intercellular adhesion molecules mentioned 
previously (141), as well as secretion of various cytokines 
that are chemotactic for monocytes. The mechanism of 
conversion to foam cells likely involves uptake of LDL that 
has been oxidatively modified by endothelial cells to modi- 
fied-LDL (142), a form with much diminished binding to the 
classic LDL receptor but with avid binding to a distinct high 
affinity receptor on endothelial cells and macrophages. This 
receptor is termed the scavenger acetyl-LDL or modified 
LDL receptor (143,144). Bound modified-LDL appears to be 
internalized through receptor-coated pits (145), after which 
cholesterol is esterified by acyl-CA:cholesterol acyltrans- 
ferase (ACAT) and may tend to accumulate because lack of 
down regulation of uptake by esterified cholesterol (146). 
The major component of LDL in atherosclerotic plaque is 
modified-LDL (147,148), which is toxic to proliferating cells 
(141,149) and may thus create a vicious cycle of injury, 
macrophage invasion and modified-LDL accumulation. 
Modification of VLDL (very low density lipoprotein) by 
oxidation followed by receptor-mediated uptake may play a 
similar role in macrophage cholesterol ester overload and 
injury (150). 
Abnormal LDL metabolism. Several atherogenic inher- 
ited abnormalities in LDL metabolism have been identified, 
the classic example being the group of abnormalities in the 
LDL receptor associated with familial hypercholesterolemia 
(151). Others are due to abnormal LDL constituent apopro- 
teins. such as apo B (152) or apo E and have been exten- 
sively reviewed (153,154). The atherogenicity of all these 
diseases is presumably referable to increased interaction of 
LDL with endothelial cells or macrophages, or both, as a 
result of either elevated levels or affinities, then leading to 
increased accumulation of modified-LDL and the attendant 
damage. 
Abnormalities in the normal removal of cholesterol from 
cholesterol ester-laden macrophages by high density lipopro- 
tein (155) caused by mutations in its constituents such as apo 
A (156) can also lead to atherosclerosis, again presumably 
due to resulting elevated local concentrations of modified- 
LDL and its associated toxicity. 
Neointimal hyperplasia and monoclonal proliferation. The 
next phase of atherosclerosis involving smooth muscle cell 
migration to and growth in the subendothelial region, termed 
neointimal hyperplasia, has been viewed as the primary 
problem in the monoclonal proliferation hypothesis of Ben- 
ditt and Benditt (157) thus considering the atherosclerotic 
plaque as analogous to a benign tumor. Such loss of regula- 
tion of this process, normally involved in healing, has been 
suggested to be due to expression of abnormal transforming 
genes (158), but might alternatively be seen as a conse- 
quence of an inappropriate shift in the dynamic equilibrium 
of normal vascular myocyte populations between a “con- 
tractile phase” and a “proliferative phase” (124), toward the 
latter. This action might occur by loss of regulation of 
normal proto-oncogenes or growth factors. Interconversion 
between two such phenotypes of vascular myocytes would 
involve concerted up-regulation and down-regulation of the 
multiple genes required for determining each phenotype. 
Although such conversions are difficult to demonstrate in 
vivo, they are readily observable in cell culture (124). It is 
interesting to note that the contraction, migration and repli- 
cation responses of the respective cell types are regulated in 
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parallel by many factors, such that those species directly 
favoring contraction will often be chemotactic and mitogenic 
(that is, serotonin, platelet-derived growth factor); the con- 
verse is also often true (for example, prostacyclin). 
Such concepts of hyperproliferation due either to expres- 
sion of an abnormal gene or to abnormal expression of a 
normal gene have precedents in oncology; many human 
cancers are caused by single amino acid mutations of the ras 
proto-oncogene to a transforming protein (1%162), whereas 
Burkitt’s lymphoma is caused by abnormal regulation of a 
normal myc proto-oncogene (163,164). Smooth muscle hy- 
perplasia by either of these mechanisms could be mediated 
intracellularly by autocrine hyperstimulation in which indi- 
vidual cells both synthesize and respond to a mitogenic 
stimulus. They could also be stimulated by intercellular 
mechanisms involving paracrine response to the secretion by 
neighboring cells of either elevated levels of growth factors 
or insufficient growth inhibiting factors (chalones). Evidence 
for each of these mechanisms exists, and recognition of the 
remarkable homology between the oncogene v-sis and the 
B-chain of the platelet-derived growth factor (165,166) in 
conjunction with the discovery of expression of significantly 
elevated amounts of both the A and B chains of platelet- 
derived growth factor in atherosclerotic lesions (167,168) has 
implicated this factor as one of the more important in their 
etiology. 
Platelet derived growth factor. This factor is one of the 
primary constituents of the platelet alpha-granule, but one or 
both of its chains can also be synthesized and generated by 
several other cells, including endothelial cells, macrophages 
and even smooth muscle in early stages of development 
when stressed (169). It is a powerful chemotactic agent as 
well as the major mitogen for smooth muscle (170). There is 
evidence that it serves as a vasoconstrictor as well (171). 
Although human platelet-derived growth factor is a hetro- 
dimer of the homologous A and B chains, other cells may 
secrete instead or in addition a homodimeric protein (that is, 
AA or BB). Macrophages appear to strongly favor B chains, 
smooth muscle cells favor A chains, and endothelial cells 
exhibit independent regulation of the two by agents such as 
thrombin and transforming growth factor-beta (TGF-beta) 
(172-175). All forms are mitogenic with greater potency 
of the B-chain (176,177). A platelet-derived growth fac- 
tor receptor was cloned in 1986 (178), and recently two re- 
ceptors have been described with differing specificities 
(176,179,180). Paracrine stimulation by these chains from 
platelets and arterial cells under the abnormal conditions 
predisposing to atherosclerosis likely accounts for a major 
proportion of the dysfunctional muscular proliferation (Fig. 
4). Although expression in vascular myocytes normally 
seems reserved to early stages of vascular development 
(181), its presence in neointimal muscle suggests that a 
vicious cycle of autocrine self-stimulation may have oc- 
curred with expression of the factor and receptor in the same 
cell, much as is seen in cells that are transformed by the 
homologous v-sis oncogene (182). As noted, such expression 
might represent that of a normal gene or an altered, trans- 
forming gene (183); the reason for such a mutation in the 
gene or its controlling element is unclear but could reflect 
injury by free radicals induced by macrophages or endothe- 
lial cells. It could also be caused by lipid-soluble carcinogens 
delivered by LDL (184), which is believed to be important in 
effecting delivery to cells of several lipid-soluble species 
such as cyclosporine (185). 
Many other paracrine and autocrine factors present in 
platelets and atheroma cells are mitogenic toward vascular 
myocytes and also lead to other contractile or metabolic 
changes (Fig. 4); these include endothelial cell growth factor, 
interleukin-1 (186a), its derivative alpha-fibroblast growth 
factor (alpha-FGF) and its homolog beta-fibroblast growth 
factor (beta-FGF) (186), serotonin (187) and thrombospondin 
(188). Various neurotransmitters and hormones such as 
catecholamines (189) and angiotensin II (190) are likewise 
implicated in myocyte growth regulation. The endothelial 
cell growth factor group of factors is mitogenic in a paracrine 
and autocrine fashion for both endothelium and smooth 
muscle (191,192) and induce angiogenesis. These factors are 
beneficial in helping repair endothelial breaks that could lead 
to thrombogenesis and the described series of events; but 
might also be detrimental by their stimulation of endothelial 
cells and by induction of neovascularization of plaques with 
the possibility of subsequent intraplaque hemorrhage and 
rupture (193). Angiogenin is another, unrelated angiogenic 
factor, but it is not a strong mitogen (194). 
A$nal contribution to unregulated smooth muscle prolif- 
eration might be deficiency of local growth inhibitors such as 
prostacyclin and the heparin-like molecules on the endothe- 
lial surface after endothelial injury (195,196). Changes in the 
heparan component of atheroma matrix could have a similar 
effect (197,198). 
Other contributing agents and mechanisms in atheroma 
formation. The accumulation of additional lipid to form the 
neointimal foam cells of smooth muscle, rather than macro- 
phage origin as identified by typical antibody staining (199) 
may occur by somewhat different mechanisms involving 
either oncogenic transformation (200) after many cycles of 
replication or transfer of lipid from macrophage-derived 
foam cells (201) because the smooth muscle cells do not 
possess the scavenger LDL receptor. Conversely, endothe- 
lial cells appear to stimulate hydrolysis of cholesterol esters 
by smooth muscle cells (202). 
Observations of lipid accumulations in conjunction with 
herpes viruses frequently detected in plaque myocytes have 
suggested viruses as additional possible contributing agents 
to atheroma formation (203,204). Yet another molecular 
mechanism for atherosclerosis has been suggested by the 
recent cloning of the ape(a) component of the lipoprotein 
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Lp(a), a little known variant of LDL that is characterized by 
the presence of the protein ape(a) in disulfide linkage to 
apo-B-100 (205). Elevations of Lp(a) have been associated in 
many studies with atherosclerosis as a risk factor indepen- 
dent of the typical lipoprotein profile (206). The ape(a) 
component is characterized by multiple repetitions of a 
“kringle” structure similar to that employed by plasminogen 
and tissue plasminogen activator (t-PA) for fibrin binding, 
but the mechanism by which elevated Lp(a) predisposes to 
atherogenesis has not been elucidated. 
Diagnostic methods and therapeutic interventions. Under- 
standing of the specific autocrine and paracrine interactions 
mediated by the numerous growth factors depicted in Figure 
4 should afford many opportunities for development of 
diagnostic methods as well as therapeutic interventions for 
early detection and treatment of atherosclerosis. The imme- 
diate diagnostic possibilities are likely to include evaluations 
for genetic predispositions to atherosclerotic and other dis- 
eases by methods of restriction fragment length polymorph- 
isms (207). Detection of areas of endothelial denudation or 
platelet activation by appropriate radiolabeled monoclonal 
antibodies could allow local mechanical interventions such 
as laser “sealing” (208,209) or use of antibodies to deliver in 
a targeted fashion drugs such as growth factor modulators or 
antimitotic agents. 
Administration of n-3 fatty acids has been successjirl 
recently in reduction of postangioplasty restenosis (210) and 
several other methods for interfering with the pathways 
depicted in Figure 4 are also being considered as ways to 
avoid this cause of much morbidity (211,212). The known 
effects of n-3 fatty acids to diminish intimal hyperplasia may 
relate to their capacity to inhibit endothelial secretion of 
platelet-derived growth factor homologs (213). The prelimi- 
nary use of cyclosporine to prevent immune-mediated com- 
ponents of vascular injury observed in the post-transplant 
setting has been promising in animals (214) and may reflect 
the beginning of an era of atherosclerosis treatment with the 
use of agents designed to suppress or mimic various biologic 
cytokines as directed by understanding of their roles. 
Selected areas for research might include blockade of the 
expression of platelet derived growth factor or its receptor; 
or the platelet-derived growth factor-receptor interaction 
itself by inhibitors such as suramin (215) or antibodies or 
peptide fragments intended to compete for binding. Con- 
versely, antibody-directed delivery of endothelial growth- 
stimulating agents to promote coverage of denuded areas of 
endothelium might be promising, as could some means of 
modulation of the genes expressed on the endothelial surface 
that govern interactions with blood elements. Along similar 
lines, it is exciting to note the recent treatment of LDL 
receptor-deficient fibroblasts by transfer of the LDL recep- 
tor gene, which successfully resulted in expression of func- 
tional LDL receptors (215a). 
Thrombosis and Thrombolysis 
Antithrombotic properties of endothelium. The process of 
intravascular thrombosis, like that of atherosclerosis, is 
complex and requires the cooperative interaction of several 
elements. That coronary occlusion is a result of thrombus 
formation, and causes myocardial infarction are not new 
ideas (216), but the strongest supporting evidence has been 
obtained in more recent years (128). Both myocardial infarc- 
tion and unstable angina pectoris are associated with ulcer- 
ation of atherosclerotic plaques (130), thus underscoring the 
importance of endothelium as an important line of defense 
against arterial thrombosis. Some of the antithrombotic 
properties of endothelium include production of prostacyclin 
and endothelial-derived relaxation factor (EDRF) that inhibit 
platelet aggregation (217), the presence of heparin-like poly- 
saccharides on the cell surface (218), the presence on the 
surface of thrombomodulin, which participates in generation 
of anticoagulants (132), and an affinity for tissue plasminogen 
activator as well as plasminogen (219). The antithrombotic 
properties of the endothelium can be diminished by a wide 
range of factors. Hypercholesterolemia (116), immune injury 
as in transplantation (220) and circulating factors such as 
cytokines (221) can impair normal endothelial function. 
Moreover, the injured endothelium has the capacity to 
facilitate thrombosis by binding factor VII(a) (132) and 
expressing tissue factor activator (132) and by secreting 
platelet activating factor (107) and plasminogen activator 
inhibitor (222). 
Tissue plasminogen activator. The two major constituents 
of the thrombus, fibrin and platelets, continue to receive 
considerable attention. The isolation, DNA cloning and large 
scale production of tissue plasminogen activator (t-PA) by 
recombinant DNA technology has opened a new era in the 
treatment of myocardial infarction (223,224). Although intra- 
venous t-PA has proved effective in clinical studies and is 
available for broad usage, much current research is directed 
to improving several features of the molecule on the basis of 
sound principles of protein structure-function. Attempts to 
engineer the molecule are aimed at enhancing affinity for 
fibrin, improving specificity, lengthening half-life and reduc- 
ing interaction with endogenous inhibitors. Such strategies 
as modifying the glycosylation state for prolonging the 
half-life (225) and covalently linking t-PA to fibrin-specific 
monoclonal antibodies (226) are only two examples of at- 
tempts to improve clinical efficacy. 
Plasminogen activator inhibitors. There are at least three 
types of plasminogen activator inhibitors (PAI). Serum lev- 
els of these inhibitors have been shown to be elevated in 
patients with thrombotic disorders and atherosclerosis (227) 
and are increased with inflammation or infection (228). 
Plasminogen activator inhibition is important not only be- 
cause of the potential problem it poses for t-PA treatment of 
patients with myocardial infarction but also because it may 
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be one component in the overall pathogenesis of vascular 
disease. It is not surprising, therefore, that efforts to under- 
stand the tissue expression and regulation of secretion of 
plasminogen activator inhibitors are especially intense. In 
addition, at the protein structural level, genetic engineering 
strategies to produce a synthetic t-PA devoid of affinity for 
such inhibitors may be especially fruitful. 
Platelet aggregation inhibitors. The platelet is not only a 
major constituent of the thrombus but also the source of 
powerful vasoconstrictors that can cause vasospasm and 
enhance coagulation by diminished blood flow (132). Platelet 
aggregation and re-thrombosis after recanalization of arter- 
ies by t-PA is a significant drawback for present thrombo- 
lytic therapy. Thus, the development of more efficacious 
agents (both potent and selective) to inhibit the cyclooxy- 
genase (229) and lipoxygenase (10.5) pathways that produce 
platelet-aggregating prostaglandins, thromboxanes and leu- 
kotrienes is needed. Moreover, the recent demonstration 
that antibodies directed against platelet surface glycopro- 
teins expressed on activation (that is, thrombospondin and 
GIIb/IIIa) effectively inhibit aggregation suggests new pos- 
sibilities for preventing the platelet aggregates enmeshed in 
fibrin that are resistant to thrombolysis (230). 
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